110 results
8-K
EX-99.1
IMVT
Immunovant Inc
12 Feb 24
Results of Operations and Financial Condition
7:02am
approach, clinical trial design, indication selection, and general development progress; future clinical trials may not confirm any safety, potency
8-K
EX-99.1
IMVT
Immunovant Inc
9 Jan 24
Regulation FD Disclosure
8:08am
, and general development progress; future clinical trials may not confirm any safety, potency, or other product characteristics described or assumed
8-K
IMVT
Immunovant Inc
20 Dec 23
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
4:37pm
proof-of-concept trial is an open-label study to assess the safety and efficacy of batoclimab in Graves’ disease. Patients who are hyperthyroid despite … was generally well tolerated with no new safety signals observed in the initial data set.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
8-K
EX-99.1
IMVT
Immunovant Inc
20 Dec 23
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
4:37pm
exceeded 50% response rates.
This Phase 2 proof-of-concept trial is an open-label study to assess the safety and efficacy of batoclimab in Graves’ disease … ATD was discontinued. Batoclimab was generally well tolerated with no new safety signals observed in the initial data set.
“We believe the enrolled
8-K
EX-99.1
mmsp unfq8
28 Nov 23
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
7:43am
8-K
EX-99.2
hyz7thjao1cwua6ko
28 Nov 23
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
7:43am
8-K
EX-99.1
42qsxi0
9 Nov 23
Results of Operations and Financial Condition
7:06am
424B5
ibx 0y4ik48nb8
29 Sep 23
Prospectus supplement for primary offering
4:48pm
424B5
zsaez7wq
26 Sep 23
Prospectus supplement for primary offering
5:28pm
8-K
EX-99.1
2jknpwrd3c1 yvx
26 Sep 23
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
7:45am
8-K
EX-99.2
5lvynvv9s8h
26 Sep 23
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
7:45am
8-K
EX-99.1
1bsokldjgv4 hza
10 Aug 23
Results of Operations and Financial Condition
7:10am
8-K
EX-99.1
0ulmz09
22 May 23
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
ib9r7 5iowr0rce7w02
22 May 23
Results of Operations and Financial Condition
7:03am
8-K
EX-99.1
e6g2ftql
8 Dec 22
Regulation FD Disclosure
7:06am